UCLB Spinout Orchard Therapeutics Announces $150 Million Series C Financing to Advance Gene Therapy Pipeline

13 August 2018

UCLB spinout company, Orchard Therapeutics, a biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, today announced the completion of an oversubscribed $150 million Series C financing.

Based on research arising from the groups of Prof. Bobby Gaspar and Prof. Adrian Thrasher at the UCL Institute of Child Health, Orchard Therapeutics was founded in 2015 through a partnership between UCLB and F Prime Capital Partners.

Read more about this story here.

2018-08-13T09:35:59+00:00